Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
Azitra reported a Q2 net loss of $3.3 million, or $0.17 per share, while significantly bolstering its balance sheet with cash and cash equivalents rising to $6.7 million from $2.1 million at the end of 2025. The company announced positive preclinical data for its ATR-COSF cosmetic program, demonstrating anti-wrinkle activity in ex vivo human skin, and remains on track to report topline data from the first cohort of its Phase 1/2 ATR-04 trial by year-end.
Key figures
- Net loss
- 3347660
- Ga expenses
- 2067639
- Rd expenses
- 1351529
- Weighted avg shares
- 19300704
- Cash and equivalents
- 6727810
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.